FDA approves Ebanga (ansuvimab-zykl) for Zaire ebolavirus treatment (fda.gov)

• FDA approved Ebanga (ansuvimab-zykl) for Zaire ebolavirus treatment
• Monoclonal antibody previously under emergency use
• Expands therapeutic options for Ebola outbreak response

"The US Food and Drug Administration has approved Ebanga (ansuvimab-zykl), a monoclonal antibody, for the treatment of Zaire ebolavirus. This approval expands the available therapeutic options for Ebola virus disease outbreaks, providing healthcare providers with an additional tool to combat the virus. Ebanga was previously used under emergency use authorization during outbreaks and now has full FDA approval based on clinical trial data demonstrating its efficacy and safety."